Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

VKTXViking Therapeutics, Inc.

Nasdaq · CIK 0001607678
Filer categoryLarge accelerated filer
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts270

Identity from submissions API

NameViking Therapeutics, Inc.
CIK0001607678
TickersVKTX
ExchangesNasdaq
Entity typeoperating
CategoryLarge accelerated filer
SIC2834 Pharmaceutical Preparations
EIN461073877
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone858-704-4660
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
9920 PACIFIC HEIGHTS BLVD, SUITE 500
SAN DIEGO
CA
CA
Mailing address
9920 PACIFIC HEIGHTS BLVD, SUITE 500
SAN DIEGO
CA
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

652 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-05 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-002856 005-88828 261526319 34 11706
2026-10-29 10-Q 10-Q 0001193125-26-436432 001-37355 261496813 34 10286519 1 1
2026-10-28 8-K 8-K 2.02,9.01 0001193125-26-436145 001-37355 261495848 34 524444 1 1
2026-09-28 8-K 8-K 1.01,2.03,9.01 0001193125-26-405580 001-37355 261418399 34 3747206 1 1
2026-09-25 424B5 424B5 0001193125-26-401385 333-297820 261406033 33 1815013 1 1
2026-09-25 424B5 424B5 0001193125-26-401384 333-297820 261406032 33 1227246 1 1
2026-09-24 FWP FREE WRITING PROSPECTUS 0001213900-26-102798 333-297820 261402077 34 52360
2026-09-24 305B2 APPLICATION FOR DESIGNATION OF A NEW TRUSTEE 0001213900-26-102782 333-297820 261402012 33 458823
2026-09-23 424B5 424B5 0001193125-26-399628 333-297820 261401662 33 1629073
2026-09-23 424B5 424B5 0001193125-26-399627 333-297820 261401661 33 1074466
2026-09-22 8-K 8-K 8.01,9.01 0001193125-26-397219 001-37355 261395230 34 372074 1 1
2026-08-07 4 4 0002144542-26-000004 7054
2026-08-07 3 3 0002144542-26-000003 13376
2026-07-30 S-3ASR S-3ASR 0001193125-26-324455 333-297820 261219778 33 2161995 1 1
2026-07-29 4 4 0001193125-26-324448 7179
2026-07-29 4 4 0001193125-26-324447 7484
2026-07-29 4 4 0001193125-26-324446 7380
2026-07-29 10-Q 10-Q 0001193125-26-324219 001-37355 261218930 34 10074813 1 1
2026-07-29 144 xsl144X01/primary_doc.xml 0001950047-26-007394 001-37355 261217806 33 4712
2026-07-29 8-K 8-K 2.02,9.01 0001193125-26-323652 001-37355 261217383 34 462676 1 1
2026-07-29 144 xsl144X01/primary_doc.xml 0001950047-26-007380 001-37355 261217334 33 4726
2026-07-29 144 xsl144X01/primary_doc.xml 0001950047-26-007376 001-37355 261217310 33 4729
2026-06-03 4 4 0001193125-26-256039 5405
2026-06-03 3 3 0001193125-26-256038 13248
2026-05-26 8-K 8-K 5.07,9.01 0001193125-26-239535 001-37355 261020718 34 209288 1 1
2026-04-30 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002100119-26-001179 005-88828 26923391 34 7411
2026-04-30 10-Q 10-Q 0001193125-26-193315 001-37355 26919568 34 8502302 1 1
2026-04-29 8-K 8-K 2.02,9.01 0001193125-26-191487 001-37355 26915804 34 394226 1 1
2026-04-01 ARS ARS 0001193125-26-137931 001-37355 26828437 34 1278605
2026-04-01 DEFA14A DEFA14A 0001193125-26-137924 001-37355 26828377 34 367068
2026-04-01 DEF 14A DEF 14A 0001193125-26-137915 001-37355 26828323 34 4125139 1 1
2026-03-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-002541 005-88828 26805110 34 7176
2026-03-10 4 4 0001193125-26-100581 4407
2026-02-11 10-K 10-K 0001193125-26-046876 001-37355 26622128 34 13600726 1 1
2026-02-11 8-K 8-K 2.02,9.01 0001193125-26-046536 001-37355 26620740 34 476283 1 1
2026-01-26 4 4 0001193125-26-023030 5283
2026-01-26 3 3 0001193125-26-023025 13262
2026-01-05 4 4 0001193125-26-003116 17384
2026-01-05 4 4 0001193125-26-003115 17488
2026-01-05 4 4 0001193125-26-003113 17332
2026-01-05 4 4 0001193125-26-003112 6738
2026-01-05 4 4 0001193125-26-003111 6768
2026-01-05 4 4 0001193125-26-003110 6739
2026-01-05 4 4 0001193125-26-003109 12080
2026-01-05 4 4 0001193125-26-003108 6761
2026-01-05 144 xsl144X01/primary_doc.xml 0001950047-26-000106 001-37355 26506896 33 6604
2026-01-05 144 xsl144X01/primary_doc.xml 0001950047-26-000105 001-37355 26506787 33 6595
2026-01-05 144 xsl144X01/primary_doc.xml 0001950047-26-000104 001-37355 26506730 33 6583
2026-01-02 144 xsl144X01/primary_doc.xml 0001950047-26-000086 001-37355 26502957 33 4680
2025-11-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-002861 005-88828 251452816 34 11441
2025-10-28 4 4 0001193125-25-254304 7203
2025-10-28 4 4 0001193125-25-254300 15179
2025-10-28 4 4 0001193125-25-254299 7187
2025-10-28 4 4 0001193125-25-254298 7211
2025-10-28 144 xsl144X01/primary_doc.xml 0001950047-25-008235 001-37355 251425363 33 4702
2025-10-28 144 xsl144X01/primary_doc.xml 0001950047-25-008234 001-37355 251425323 33 4705
2025-10-28 144 xsl144X01/primary_doc.xml 0001950047-25-008233 001-37355 251425198 33 4677
2025-10-27 144 xsl144X01/primary_doc.xml 0001950047-25-008201 001-37355 251420183 33 5894
2025-10-23 10-Q 10-Q 0001193125-25-247059 001-37355 251410933 34 9170896 1 1
2025-10-22 8-K 8-K 2.02,9.01 0001193125-25-246775 001-37355 251410228 34 475855 1 1
2025-08-19 8-K 8-K 7.01,9.01 0001607678-25-000003 001-37355 251229635 34 325555 1 1
2025-08-06 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-002155 005-88828 251188536 34 11223
2025-07-23 10-Q 10-Q 0000950170-25-097950 001-37355 251143738 34 9127422 1 1
2025-07-23 8-K 8-K 2.02,9.01 0000950170-25-097885 001-37355 251143156 34 465651 1 1
2025-07-03 4 4 0000950170-25-093793 7070
2025-07-03 4 4 0000950170-25-093792 7088
2025-07-03 4 4 0000950170-25-093791 7086
2025-07-03 144 xsl144X01/primary_doc.xml 0001950047-25-004829 001-37355 251104674 33 4727
2025-07-03 144 xsl144X01/primary_doc.xml 0001950047-25-004828 001-37355 251104651 33 4730
2025-07-03 144 xsl144X01/primary_doc.xml 0001950047-25-004825 001-37355 251104612 33 4711
2025-05-27 8-K 8-K 5.07,9.01 0000950170-25-077865 001-37355 25989961 34 180810 1 1
2025-05-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-001596 005-88828 25933363 34 11606
2025-04-24 10-Q 10-Q 0000950170-25-058129 001-37355 25868176 34 10058162 1 1
2025-04-23 DEFA14A DEFA14A 0000950170-25-057537 001-37355 25862795 34 520962
2025-04-23 DEFR14A DEFR14A 0000950170-25-057535 001-37355 25862784 34 3640546 1 1
2025-04-23 8-K 8-K 2.02,9.01 0000950170-25-057337 001-37355 25861427 34 402843 1 1
2025-04-23 8-K 8-K 4.01,8.01,9.01 0000950170-25-057323 001-37355 25861333 34 170747 1 1
2025-04-23 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-000430 005-88828 25859546 34 11314
2025-04-21 UPLOAD filename1.pdf 0000000000-25-004171 001-37355 39611
2025-04-14 4 4 0000950170-25-053867 6402
2025-04-08 4/A 4/A 0000950170-25-052255 5291
2025-04-08 CORRESP filename1.htm 0000950170-25-052253 32623
2025-04-08 ARS ARS 0000950170-25-052204 001-37355 25823037 34 1705138
2025-04-08 DEFA14A DEFA14A 0000950170-25-052198 001-37355 25823023 34 514804
2025-04-08 DEF 14A DEF 14A 0000950170-25-052162 001-37355 25822731 34 3542603 1 1
2025-04-02 4 4 0000950170-25-049717 4368
2025-03-31 UPLOAD filename1.pdf 0000000000-25-003431 001-37355 44166
2025-03-11 8-K 8-K 1.01,2.03,8.01,9.01 0000950170-25-036820 001-37355 25725831 34 227695 1 1
2025-02-26 10-K 10-K 0000950170-25-027824 001-37355 25670673 34 13524207 1 1
2025-02-05 8-K 8-K 2.02,9.01 0000950170-25-014464 001-37355 25593302 34 480316 1 1
2025-02-04 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-25-000647 005-88828 25587844 34 12086
2025-01-06 4 4 0000950170-25-002487 13004
2025-01-06 4 4 0000950170-25-002486 13017
2025-01-06 4 4 0000950170-25-002485 13207
2025-01-06 4 4 0000950170-25-002484 4994
2025-01-06 4 4 0000950170-25-002483 4964
2025-01-06 4 4 0000950170-25-002482 4965
2025-01-06 4 4 0000950170-25-002481 4970
2025-01-06 4 4 0000950170-25-002480 4988
2025-01-06 144 xsl144X01/primary_doc.xml 0001950047-25-000164 001-37355 25512514 33 6573
2025-01-06 144 xsl144X01/primary_doc.xml 0001950047-25-000163 001-37355 25512426 33 6577
2025-01-06 144 xsl144X01/primary_doc.xml 0001950047-25-000162 001-37355 25512329 33 6557
2024-11-14 SC 13G/A sayw24111431_13ga.htm 0000905148-24-003164 005-88828 241463160 34 404810
2024-11-12 SC 13G/A UnitedStates_13G__VikingTher.txt 0000932471-24-001267 005-88828 241450273 34 6569
2024-11-08 4 4 0000950170-24-124296 7836
2024-11-08 144 xsl144X01/primary_doc.xml 0001950047-24-008355 001-37355 241442394 33 4704
2024-11-04 SC 13G/A UnitedStates_13G__VikingTher.txt 0000932471-24-000703 005-88828 241422449 34 5607
2024-11-04 8-K 8-K 7.01,9.01 0000950170-24-120267 001-37355 241420692 34 340386 1 1
2024-10-28 4 4 0000950170-24-117885 33517
2024-10-28 144 xsl144X01/primary_doc.xml 0001950047-24-007913 001-37355 241401397 33 7264
2024-10-25 4 4 0000950170-24-117514 8158
2024-10-25 4 4 0000950170-24-117513 8132
2024-10-25 144 xsl144X01/primary_doc.xml 0000103623-24-000082 001-37355 241397171 33 4356
2024-10-25 144 xsl144X01/primary_doc.xml 0000103623-24-000081 001-37355 241397030 33 6739
2024-10-23 10-Q 10-Q 0000950170-24-116708 001-37355 241389720 34 8092474 1 1
2024-10-23 8-K 8-K 2.02,9.01 0000950170-24-116642 001-37355 241389314 34 442975 1 1
2024-10-18 SC 13G/A Viking_Therapeutics_Inc.htm 0000093751-24-000891 005-88828 241379619 34 56005
2024-09-20 4 4 0000950170-24-108577 8132
2024-09-20 4 4 0000950170-24-108576 12908
2024-09-20 144 xsl144X01/primary_doc.xml 0000103623-24-000077 001-37355 241313737 33 7148
2024-09-20 144 xsl144X01/primary_doc.xml 0000103623-24-000076 001-37355 241313514 33 6120
2024-08-22 4 4 0000950170-24-099982 8392
2024-08-22 4 4 0000950170-24-099980 8658
2024-08-21 144 xsl144X01/primary_doc.xml 0000103623-24-000075 001-37355 241229098 33 5549
2024-08-21 144 xsl144X01/primary_doc.xml 0000103623-24-000074 001-37355 241228951 33 5523
2024-08-19 4 4 0000950170-24-098803 12859
2024-08-19 4 4 0000950170-24-098799 18471
2024-08-19 144 xsl144X01/primary_doc.xml 0000103623-24-000073 001-37355 241222323 33 5456
2024-08-19 144 xsl144X01/primary_doc.xml 0000103623-24-000072 001-37355 241222298 33 4932
2024-08-14 4 4 0000950170-24-097325 10619
2024-08-14 144 xsl144X01/primary_doc.xml 0000103623-24-000070 001-37355 241208855 33 4360
2024-08-07 SC 13G/A us92686j1060_080724.txt 0001086364-24-008371 005-88828 241183804 34 13241
2024-07-31 4 4 0000950170-24-088538 12688
2024-07-31 4 4 0000950170-24-088544 12675
2024-07-31 4 4 0000950170-24-088537 10723
2024-07-30 144 xsl144X01/primary_doc.xml 0001950047-24-005692 001-37355 241159181 33 4714
2024-07-30 144 xsl144X01/primary_doc.xml 0001950047-24-005691 001-37355 241159173 33 4718
2024-07-30 144 xsl144X01/primary_doc.xml 0001950047-24-005690 001-37355 241159166 33 4699
2024-07-24 10-Q 10-Q 0000950170-24-086111 001-37355 241138852 34 9107853 1 1
2024-07-24 8-K 8-K 2.02,9.01 0000950170-24-086039 001-37355 241138179 34 432863 1 1
2024-06-04 8-K 8-K 7.01,9.01 0000950170-24-068297 001-37355 241016068 34 314923 1 1
2024-05-23 8-K 8-K 5.02,5.07,9.01 0000950170-24-063707 001-37355 24974944 34 205147 1 1
2024-05-23 S-8 POS S-8 POS 0000950170-24-063705 333-223503 24974924 33 141378
2024-05-23 S-8 POS S-8 POS 0000950170-24-063698 333-211270 24974870 33 288329
2024-05-23 S-8 POS S-8 POS 0000950170-24-063697 333-203810 24974867 33 288329
2024-05-23 S-8 POS S-8 POS 0000950170-24-063691 333-230247 24974855 33 288329
2024-05-23 S-8 POS S-8 POS 0000950170-24-063690 333-216857 24974851 33 288329
2024-05-23 S-8 POS S-8 POS 0000950170-24-063689 333-236666 24974848 33 288329
2024-05-23 S-8 POS S-8 POS 0000950170-24-063685 333-269675 24974834 33 288329
2024-05-23 S-8 POS S-8 POS 0000950170-24-063684 333-276939 24974831 33 288329
2024-05-23 S-8 POS S-8 POS 0000950170-24-063683 333-253219 24974829 33 288329
2024-05-23 S-8 POS S-8 POS 0000950170-24-063677 333-262609 24974810 33 288329
2024-05-22 S-8 POS S-8 POS 0000950170-24-063590 333-223503 24974295 33 284369
2024-05-22 S-8 S-8 0000950170-24-063533 333-279633 24973829 33 785979
2024-05-03 4 FORM 4 SUBMISSION 0001209191-24-005522 19715
2024-05-03 144 xsl144X01/primary_doc.xml 0000103623-24-000054 001-37355 24912952 33 7428
2024-05-02 4 FORM 4 SUBMISSION 0001209191-24-005486 33555
2024-05-01 144 xsl144X01/primary_doc.xml 0000103623-24-000052 001-37355 24902865 33 6482
2024-04-25 10-Q 10-Q 0000950170-24-047833 001-37355 24872473 34 7279387 1 1
2024-04-24 8-K 8-K 2.02,9.01 0000950170-24-047567 001-37355 24870541 34 377788 1 1
2024-04-05 ARS ARS 0000950170-24-042275 001-37355 24826686 34 792947
2024-04-05 DEFA14A DEFA14A 0000950170-24-042264 001-37355 24826564 34 253943
2024-04-05 DEF 14A DEF 14A 0000950170-24-042251 001-37355 24826464 34 3370788 1 1
2024-03-27 4 FORM 4 SUBMISSION 0001209191-24-005118 6904
2024-03-27 4 FORM 4 SUBMISSION 0001209191-24-005117 6889
2024-03-27 4 FORM 4 SUBMISSION 0001209191-24-005116 6907
2024-03-26 8-K 8-K 7.01,9.01 0000950170-24-036151 001-37355 24780882 34 261117 1 1
2024-03-04 4 FORM 4 SUBMISSION 0001209191-24-004233 6888
2024-03-04 4 FORM 4 SUBMISSION 0001209191-24-004232 6903
2024-03-04 4 FORM 4 SUBMISSION 0001209191-24-004231 6906
2024-03-04 8-K 8-K 8.01,9.01 0000950170-24-024878 001-37355 24715510 34 204270 1 1
2024-03-01 424B5 424B5 0000950170-24-023848 333-273460 24709871 33 834802
2024-03-01 8-K 8-K 1.01,8.01,9.01 0000950170-24-023838 001-37355 24709566 34 619159 1 1
2024-02-27 424B5 424B5 0000950170-24-021420 333-273460 24688616 33 807556
2024-02-27 8-K 8-K 7.01,9.01 0000950170-24-020616 001-37355 24681925 34 261097 1 1
2024-02-14 SC 13G/A sayw24021420_13ga.htm 0000905148-24-000616 005-88828 24633550 34 288709
2024-02-13 SC 13G SCHEDULE 13G 0001104659-24-022246 005-88828 24629911 34 13037
2024-02-09 4 FORM 4 SUBMISSION 0001209191-24-003068 4933
2024-02-09 144 xsl144X01/primary_doc.xml 0000103623-24-000023 001-37355 24614629 33 6117
2024-02-09 SC 13G/A filing.txt 0000315066-24-001571 005-88828 24612644 34 8262
2024-02-08 4 FORM 4 SUBMISSION 0001209191-24-003010 21388
2024-02-08 4 FORM 4 SUBMISSION 0001209191-24-003008 8697
2024-02-08 144 xsl144X01/primary_doc.xml 0000103623-24-000022 001-37355 24609921 33 8096
2024-02-08 144 xsl144X01/primary_doc.xml 0000103623-24-000021 001-37355 24609601 33 4941
2024-02-07 S-8 S-8 0000950170-24-012328 333-276939 24605998 33 174395
2024-02-07 10-K 10-K 0000950170-24-012322 001-37355 24605905 34 10701136 1 1
2024-02-07 8-K 8-K 2.02,9.01 0000950170-24-012199 001-37355 24604369 34 379095 1 1
2024-01-31 4 FORM 4 SUBMISSION 0001209191-24-002512 10552
2024-01-31 144 xsl144X01/primary_doc.xml 0000103623-24-000020 001-37355 24584088 33 5443
2024-01-30 4 FORM 4 SUBMISSION 0001209191-24-002458 8957
2024-01-30 144 xsl144X01/primary_doc.xml 0000103623-24-000019 001-37355 24578504 33 4358
2024-01-26 SC 13G us92686j1060_012624.txt 0001086364-24-004283 005-88828 24565760 34 13668
2024-01-24 SC 13G/A VikingTherapeutics.txt 0000093751-24-000183 005-88828 24555549 34 8461
2024-01-19 4 FORM 4 SUBMISSION 0001209191-24-001973 8701
2024-01-19 144 xsl144X01/primary_doc.xml 0000103623-24-000011 001-37355 24546094 33 4364
2024-01-12 SC 13G/A VKTX_SC13GA1.htm 0001273087-24-000012 005-88828 24532353 34 81662
2024-01-04 4 FORM 4 SUBMISSION 0001209191-24-000931 14781
2024-01-04 4 FORM 4 SUBMISSION 0001209191-24-000930 14745
2024-01-04 4 FORM 4 SUBMISSION 0001209191-24-000929 16824
2024-01-04 4 FORM 4 SUBMISSION 0001209191-24-000925 5224
2024-01-04 4 FORM 4 SUBMISSION 0001209191-24-000924 5225
2024-01-04 4 FORM 4 SUBMISSION 0001209191-24-000923 5248
2024-01-04 4 FORM 4 SUBMISSION 0001209191-24-000922 5254
2024-01-04 4 FORM 4 SUBMISSION 0001209191-24-000921 5230
2024-01-04 144 xsl144X01/primary_doc.xml 0001217234-24-000004 001-37355 24514156 33 4279
2023-11-02 SC 13G SC 13G 0001140361-23-051165 005-88828 231372897 34 285515
2023-10-25 10-Q 10-Q 0000950170-23-055259 001-37355 231346672 34 9119405 1 1
2023-10-25 8-K 8-K 2.02,9.01 0000950170-23-055209 001-37355 231346313 34 514413 1 1
2023-07-26 S-3ASR S-3ASR 0000950170-23-034818 333-273460 231114642 33 2238615
2023-07-26 10-Q 10-Q 0000950170-23-034773 001-37355 231114177 34 10237171 1 1
2023-07-26 8-K 8-K 2.02,9.01 0000950170-23-034741 001-37355 231113912 34 591999 1 1
2023-06-14 8-K 8-K 5.07,9.01 0000950170-23-027965 001-37355 231014417 34 229543 1 1
2023-05-18 4 FORM 4 SUBMISSION 0001209191-23-030796 8581
2023-05-18 4 FORM 4 SUBMISSION 0001209191-23-030794 8610
2023-05-16 144 xsl144X01/primary_doc.xml 0001976408-23-000005 001-37355 23928888 33 4123
2023-05-16 144 xsl144X01/primary_doc.xml 0001976408-23-000004 001-37355 23928188 33 5343
2023-05-11 8-K 8-K 5.03,9.01 0000950170-23-021359 001-37355 23911985 34 472849 1 1
2023-05-01 4 FORM 4 SUBMISSION 0001209191-23-026356 4829
2023-05-01 ARS ARS 0000950170-23-016267 001-37355 23874027 34 597176
2023-05-01 DEFA14A DEFA14A 0000950170-23-016264 001-37355 23874000 34 260551
2023-05-01 DEF 14A DEF 14A 0000950170-23-016221 001-37355 23873437 34 3919537 1 1
2023-05-01 144 xsl144X01/primary_doc.xml 0001607678-23-000003 001-37355 23872438 33 7696
2023-04-26 10-Q 10-Q 0000950170-23-014883 001-37355 23850624 34 8939599 1 1
2023-04-26 8-K 8-K 2.02,9.01 0000950170-23-014788 001-37355 23849730 34 487122 1 1
2023-04-24 4 FORM 4 SUBMISSION 0001209191-23-025473 8612
2023-04-24 144 xsl144X01/primary_doc.xml 0001607678-23-000002 001-37355 23840666 33 4888
2023-04-21 4 FORM 4 SUBMISSION 0001209191-23-025277 4829
2023-04-19 144 xsl144X01/primary_doc.xml 0001607678-23-000001 001-37355 23830583 33 7214
2023-04-18 4 FORM 4 SUBMISSION 0001209191-23-024725 8841
2023-04-18 4 FORM 4 SUBMISSION 0001209191-23-024724 8846
2023-04-18 4 FORM 4 SUBMISSION 0001209191-23-024723 8968
2023-04-18 4 FORM 4 SUBMISSION 0001209191-23-024722 8967
2023-04-17 144 xsl144X01/primary_doc.xml 0001838112-23-000005 001-37355 23825000 33 6506
2023-04-17 144 xsl144X01/primary_doc.xml 0001838112-23-000004 001-37355 23824966 33 8200
2023-04-17 144 xsl144X01/primary_doc.xml 0001838112-23-000003 001-37355 23824928 33 4220
2023-04-17 144 xsl144X01/primary_doc.xml 0001838112-23-000002 001-37355 23824845 33 6984
2023-04-17 144 xsl144X01/primary_doc.xml 0001838112-23-000001 001-37355 23824686 33 5239
2023-04-17 PRE 14A PRE 14A 0000950170-23-013104 001-37355 23824640 34 3922658 1 1
2023-04-13 4 FORM 4 SUBMISSION 0001209191-23-024228 8678
2023-04-13 4 FORM 4 SUBMISSION 0001209191-23-024227 30363
2023-04-10 SC 13G filing.txt 0000315066-23-002238 005-88828 23809898 34 8189
2023-04-03 4 FORM 4 SUBMISSION 0001209191-23-022400 25261
2023-04-03 4 FORM 4 SUBMISSION 0001209191-23-022398 29893
2023-04-03 4 FORM 4 SUBMISSION 0001209191-23-022396 20422
2023-04-03 8-K 8-K 8.01,9.01 0000950170-23-011636 001-37355 23793894 34 232640 1 1
2023-03-31 8-K 8-K 1.01,8.01,9.01 0000950170-23-011443 001-37355 23789337 34 715927 1 1
2023-03-31 424B5 424B5 0000950170-23-011441 333-258231 23789293 33 1039888
2023-03-30 4 FORM 4 SUBMISSION 0001209191-23-021743 41625
2023-03-30 SC 13D/A SC 13D/A 0001193125-23-085535 005-88828 23780756 34 32595
2023-03-29 424B5 424B5 0000950170-23-010583 333-258231 23775135 33 1071490
2023-03-28 8-K 8-K 7.01,9.01 0000950170-23-010112 001-37355 23766128 34 226139 1 1
2023-03-28 8-K 8-K 7.01,9.01 0000950170-23-010108 001-37355 23766102 34 299731 1 1
2023-02-14 SC 13G/A arrowmark-vktx123122a5.htm 0001172661-23-001442 005-88828 23632002 34 54166
2023-02-10 S-8 S-8 0001564590-23-001696 333-269675 23608294 33 163615
2023-02-10 10-K 10-K 0001564590-23-001685 001-37355 23607614 34 10929072 1 1
2023-02-09 SC 13D/A SC 13D/A 0001193125-23-030129 005-88828 23606699 34 56957
2023-02-08 8-K 8-K 2.02,9.01 0001564590-23-001611 001-37355 23599194 34 502867 1 1
2023-02-03 SC 13G/A Viking_Therapeutics_Inc.txt 0000093751-23-000183 005-88828 23585555 34 8244
2023-01-17 4 FORM 4 SUBMISSION 0001209191-23-003606 4846
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-001343 14865
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-001342 14861
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-001340 14850
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-001314 5109
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-001313 5110
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-001311 5139
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-001310 5133
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-001297 5115
2023-01-03 SC 13G VKTX_SC13G.htm 0001273087-23-000003 005-88828 23502870 34 81560
2022-10-26 10-Q 10-Q 0001564590-22-035295 001-37355 221334057 34 9080900 1 1
2022-10-26 8-K 8-K 2.02,9.01 0001564590-22-035271 001-37355 221333626 34 495478 1 1
2022-07-27 10-Q 10-Q 0001564590-22-026717 001-37355 221111790 34 9226804 1 1
2022-07-27 8-K 8-K 2.02,9.01 0001564590-22-026689 001-37355 221111138 34 517385 1 1
2022-07-08 SC 13G us92686j1060_070822.txt 0000834237-22-010314 005-88828 221075073 34 12166
2022-05-26 8-K 8-K 5.07 0001564590-22-021417 001-37355 22970044 34 183319 1 1
2022-05-03 4 FORM 4 SUBMISSION 0001209191-22-026674 4501
2022-04-27 10-Q 10-Q 0001564590-22-016129 001-37355 22860718 34 7854917 1 1
2022-04-27 8-K 8-K 2.02,9.01 0001564590-22-016110 001-37355 22860477 34 446636 1 1
2022-04-07 DEFA14A DEFA14A 0001564590-22-013879 001-37355 22814557 34 2266740
2022-04-07 DEF 14A DEF 14A 0001564590-22-013875 001-37355 22814538 34 970839
2022-02-14 SC 13G/A arrowmark-vktx123121a4.htm 0001172661-22-000676 005-88828 22629910 34 53978
2022-02-14 SC 13G/A VIKING_THERAPEUTICS_INC.txt 0000093751-22-000363 005-88828 22624240 34 8393
2022-02-11 4 FORM 4 SUBMISSION 0001209191-22-008999 4844
2022-02-09 S-8 S-8 0001564590-22-004440 333-262609 22608406 33 162353
2022-02-09 10-K 10-K 0001564590-22-004429 001-37355 22608030 34 10573554 1 1
2022-02-09 8-K 8-K 2.02,9.01 0001564590-22-004406 001-37355 22607387 34 561283 1 1
2022-02-03 SC 13G/A us92686j1060_020322.txt 0000834237-22-006335 005-88828 22589053 34 13272
2022-01-05 4 FORM 4 SUBMISSION 0001209191-22-001988 10861
2022-01-05 4 FORM 4 SUBMISSION 0001209191-22-001987 10873
2022-01-05 4 FORM 4 SUBMISSION 0001209191-22-001986 10861
2022-01-05 4 FORM 4 SUBMISSION 0001209191-22-001985 5094
2022-01-05 4 FORM 4 SUBMISSION 0001209191-22-001983 5095
2022-01-05 4 FORM 4 SUBMISSION 0001209191-22-001982 5118
2022-01-05 4 FORM 4 SUBMISSION 0001209191-22-001981 5124
2022-01-05 4 FORM 4 SUBMISSION 0001209191-22-001980 5100
2021-11-03 10-Q 10-Q 0001564590-21-054030 001-37355 211376348 34 9019413 1 1
2021-11-03 8-K 8-K 2.02,9.01 0001564590-21-053950 001-37355 211375439 34 514602 1 1
2021-09-30 4 FORM 4 SUBMISSION 0001209191-21-058253 6947
2021-09-30 4 FORM 4 SUBMISSION 0001209191-21-058249 6962
2021-09-30 4 FORM 4 SUBMISSION 0001209191-21-058246 6961
2021-08-11 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2021-08-11 16:30:00 9999999995-21-003155 333-258231 211165414 33 1696
2021-08-11 424B5 424B5 0001564590-21-043489 333-258231 211164135 33 256752
2021-08-05 CORRESP filename1.htm 0001564590-21-041580 36920
2021-08-02 UPLOAD filename1.pdf 0000000000-21-009419 40202
2021-07-28 8-K 8-K 1.01,1.02,9.01 0001564590-21-038678 001-37355 211123610 34 170392 1 1
2021-07-28 S-3 S-3 0001564590-21-038667 333-258231 211123211 33 1674238
2021-07-28 10-Q 10-Q 0001564590-21-038663 001-37355 211123138 34 8867384 1 1
2021-07-28 8-K 8-K 2.02,9.01 0001564590-21-038623 001-37355 211122671 34 500466 1 1
2021-06-10 4 FORM 4 SUBMISSION 0001209191-21-039521 4485
2021-05-21 8-K 8-K 5.07 0001564590-21-029335 001-37355 21949896 34 196412 1 1
2021-04-28 10-Q 10-Q 0001564590-21-021430 001-37355 21865176 34 7788754 1 1
2021-04-28 8-K 8-K 2.02,9.01 0001564590-21-021350 001-37355 21864338 34 424121 1 1
2021-04-08 DEFA14A DEFA14A 0001564590-21-018184 001-37355 21815240 34 1044780
2021-04-08 DEF 14A DEF 14A 0001564590-21-018175 001-37355 21815085 34 2042699
2021-04-08 25-NSE xslF25X02/primary_doc.xml 0001354457-21-000458 001-37355 21814997 34 2952
2021-03-25 4 FORM 4 SUBMISSION 0001209191-21-023130 6698
2021-02-17 S-8 S-8 0001564590-21-006421 333-253219 21645995 33 162016
2021-02-17 10-K 10-K 0001564590-21-006406 001-37355 21645599 34 10186460 1 1
2021-02-17 8-K 8-K 2.02,9.01 0001564590-21-006376 001-37355 21644853 34 542214 1 1
2021-02-16 SC 13G/A 13G/A 0001172661-21-000652 005-88828 21635603 34 53988
2021-02-11 SC 13G Viking_Therapeutics_Inc.txt 0000093751-21-000322 005-88828 21619899 34 10282
2021-02-01 SC 13G/A us92686j1060_013121.txt 0000834237-21-005734 005-88828 21574727 34 13254
2021-01-19 4 FORM 4 SUBMISSION 0001209191-21-004101 4836
2021-01-19 4 FORM 4 SUBMISSION 0001209191-21-004098 6429
2021-01-19 4 FORM 4 SUBMISSION 0001209191-21-004095 4822
2021-01-19 4 FORM 4 SUBMISSION 0001209191-21-004093 4817
2021-01-06 4 FORM 4 SUBMISSION 0001209191-21-002140 5095
2021-01-06 4 FORM 4 SUBMISSION 0001209191-21-002135 5124
2021-01-06 4 FORM 4 SUBMISSION 0001209191-21-002128 5100
2021-01-06 4 FORM 4 SUBMISSION 0001209191-21-002124 5094
2021-01-06 4 FORM 4 SUBMISSION 0001209191-21-002119 5118
2021-01-06 4 FORM 4 SUBMISSION 0001209191-21-002114 11201
2021-01-06 4 FORM 4 SUBMISSION 0001209191-21-002104 13009
2021-01-06 4 FORM 4 SUBMISSION 0001209191-21-002086 11036
2021-01-06 4 FORM 4 SUBMISSION 0001209191-21-002074 11036
2021-01-06 3 FORM 3 SUBMISSION 0001209191-21-002053 16305
2021-01-06 3 FORM 3 SUBMISSION 0001209191-21-002036 27294
2021-01-06 8-K 8-K 5.02,9.01 0001564590-21-000409 001-37355 21510729 34 214792 1 1
2020-10-28 10-Q 10-Q 0001564590-20-048398 001-37355 201269409 34 8525742 1 1
2020-10-28 8-K 8-K 2.02,9.01 0001564590-20-048337 001-37355 201268747 34 531280 1 1
2020-09-16 4 FORM 4 SUBMISSION 0001209191-20-050734 6887
2020-09-16 4 FORM 4 SUBMISSION 0001209191-20-050732 6900
2020-08-28 SC 13D/A SC 13D/A 0001193125-20-234860 005-88828 201148778 34 54812
2020-08-28 4/A FORM 4/A SUBMISSION 0000899243-20-023644 5831
2020-08-27 4 FORM 4 SUBMISSION 0000899243-20-023546 7065
2020-07-29 10-Q 10-Q 0001564590-20-034329 001-37355 201057866 34 8370994 1 1
2020-07-29 8-K 8-K 2.02,9.01 0001564590-20-034308 001-37355 201057600 34 533726 1 1
2020-06-30 4 FORM 4 SUBMISSION 0001209191-20-039521 4485
2020-05-21 8-K 8-K 5.07 0001564590-20-026582 001-37355 20902648 34 46591
2020-05-20 DEFA14A DEFA14A 0001564590-20-026393 001-37355 20898488 34 42489
2020-04-30 10-Q 10-Q 0001564590-20-020233 001-37355 20836559 34 6483165 1
2020-04-30 8-K 8-K 2.02,9.01 0001564590-20-020180 001-37355 20835753 34 273132
2020-04-06 DEFA14A DEFA14A 0001564590-20-015533 001-37355 20777452 34 858840
2020-04-06 DEF 14A DEF 14A 0001564590-20-015522 001-37355 20777309 34 1823936
2020-04-03 4 FORM 4 SUBMISSION 0001209191-20-023378 5364
2020-03-17 8-K 8-K 7.01 0001564590-20-011413 001-37355 20721235 34 26200
2020-02-26 S-8 S-8 0001564590-20-006838 333-236666 20656906 33 152514
2020-02-26 10-K 10-K 0001564590-20-006766 001-37355 20655596 34 9031960 1
2020-02-19 CT ORDER filename1.pdf 20200219,20200219 9999999997-20-000814 333-197182 20630410 33 122148
2020-02-14 SC 13G/A SCHEDULE 13G HOLDINGS REPORT AMENDMENT 0001172661-20-000911 005-88828 20621133 34 54023
2020-02-13 SC 13G/A VikingTherapeut.txt 0000093751-20-000478 005-88828 20611140 34 8498
2020-02-07 SC 13G/A filing.txt 0000315066-20-001268 005-88828 20586011 34 8435
2020-02-06 SC 13G/A us92686j1060_020520.txt 0000834237-20-006932 005-88828 20581421 34 13224
2020-01-21 4 FORM 4 SUBMISSION 0001209191-20-004314 4830
2020-01-21 4 FORM 4 SUBMISSION 0001209191-20-004311 5029
2020-01-03 4 FORM 4 SUBMISSION 0001209191-20-001428 5364
2020-01-03 4 FORM 4 SUBMISSION 0001209191-20-001426 9298
2020-01-03 4 FORM 4 SUBMISSION 0001209191-20-001425 5136
2020-01-03 4 FORM 4 SUBMISSION 0001209191-20-001422 5094
2020-01-03 4 FORM 4 SUBMISSION 0001209191-20-001421 5100
2020-01-03 4 FORM 4 SUBMISSION 0001209191-20-001420 5124
2020-01-03 4 FORM 4 SUBMISSION 0001209191-20-001419 5095
2020-01-03 4 FORM 4 SUBMISSION 0001209191-20-001418 5118
2019-11-05 10-Q 10-Q 0001564590-19-040424 001-37355 191193774 34 7480469 1
2019-11-05 8-K 8-K 2.02,9.01 0001564590-19-040059 001-37355 191191737 34 345533
2019-10-31 4 FORM 4 SUBMISSION 0001209191-19-054654 5362
2019-10-10 SC 13G/A SCHEDULE 13G HOLDINGS REPORT AMENDMENT 0001172661-19-002034 005-88828 191146231 34 54026
2019-08-02 4 FORM 4 SUBMISSION 0001209191-19-044336 5361
2019-08-02 8-K 8-K 1.01,9.01 0001564590-19-028063 001-37355 19993864 34 281114
2019-08-02 424B5 424B5 0001564590-19-028058 333-226133 19993784 33 608568
2019-08-01 10-Q 10-Q 0001564590-19-028043 001-37355 19993609 34 7471376 1
2019-08-01 8-K 8-K 2.02,9.01 0001564590-19-027983 001-37355 19993041 34 346962
2019-07-02 4 FORM 4 SUBMISSION 0001209191-19-040272 5089
2019-07-02 3 FORM 3 SUBMISSION 0001209191-19-040257 6099
2019-07-02 8-K 8-K 5.02,9.01 0001564590-19-024412 001-37355 19937506 34 56030
2019-05-23 8-K 8-K 5.07 0001564590-19-020346 001-37355 19850790 34 47113
2019-05-02 10-Q 10-Q 0001564590-19-015390 001-37355 19792952 34 6930359 1
2019-05-02 8-K 8-K 2.02,9.01 0001564590-19-015327 001-37355 19791875 34 289960
2019-04-10 SC 13G/A VIKING THERAPEUTICS, INC. 0000093751-19-000378 005-88828 19741334 34 10542
2019-04-05 DEFA14A DEFA14A 0001564590-19-010933 001-37355 19735607 34 412489
2019-04-05 DEF 14A DEF 14A 0001564590-19-010928 001-37355 19735420 34 1258716
2019-03-13 S-8 S-8 0001564590-19-007589 333-230247 19679381 33 149177
2019-03-13 10-K 10-K 0001564590-19-007584 001-37355 19678832 34 9719100 1
2019-03-13 8-K 8-K 2.02,9.01 0001564590-19-007569 001-37355 19678385 34 335556
2019-02-14 SC 13G/A SC 13G/A 0001193125-19-040832 005-88828 19606382 34 52618
2019-02-14 SC 13G arrowmark-vktx123118.htm 0001172661-19-000513 005-88828 19600818 34 53946
2019-02-13 SC 13G/A SC 13G/A 0001178913-19-000440 005-88828 19598522 34 137539
2019-02-13 SC 13G/A filing.txt 0000315066-19-001442 005-88828 19595267 34 8389
2019-02-13 SC 13G VIKING THERAPEUTICS, INC. 0000093751-19-000115 005-88828 19593839 34 10548
2019-02-08 SC 13G us92686j1060_020719.txt 0000215457-19-006859 005-88828 19576668 34 13157
2019-01-22 4 FORM 4 SUBMISSION 0001209191-19-004861 4817

Latest XBRL company facts

One latest value per concept from companyfacts (270 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 127.52M 2026-10-15 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
dei EntityPublicFloat Entity Public Float USD 2.98B 2025-06-30 2025 FY 10-K 2026-02-11 0001193125-26-046876
ffd NetFeeAmt NetFeeAmt USD 43,674.12 2026-09-24 424B5 2026-09-25 0001193125-26-401384
ffd NrrtvMaxAggtAmt NrrtvMaxAggtAmt shares 9.04M 2026-09-24 424B5 2026-09-25 0001193125-26-401384
ffd NrrtvMaxAggtOfferingPric NrrtvMaxAggtOfferingPric USD 316.25M 2026-09-24 424B5 2026-09-25 0001193125-26-401384
ffd TtlFeeAmt TtlFeeAmt USD 43,674.12 2026-09-24 424B5 2026-09-25 0001193125-26-401384
ffd TtlOfferingAmt TtlOfferingAmt USD 316.25M 2026-09-24 424B5 2026-09-25 0001193125-26-401384
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-09-24 424B5 2026-09-25 0001193125-26-401384
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-09-24 424B5 2026-09-25 0001193125-26-401384
srt StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased shares 633,810 2015-05-31 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 82.13M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 2.97M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax USD -1.70M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 1.91B 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD 456,412 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-08 0001564590-16-014212
us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition USD 39.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 2.60M 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-08 0001564590-16-014212
us-gaap AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006766
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 12.65M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap Assets Assets USD 977.17M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap AssetsCurrent Assets, Current USD 973.00M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 835.53M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 1,000 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 1.22M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 283.43M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap AvailableForSaleSecurities Available-for-sale Securities USD 13.34M 2015-12-31 2015 FY 10-K 2016-03-08 0001564590-16-014212
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax USD 416 2016-03-31 2016 Q1 10-Q 2016-05-10 0001564590-16-018987
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax USD 611 2016-03-31 2016 Q1 10-Q 2016-05-10 0001564590-16-018987
us-gaap AvailableForSaleSecuritiesAmortizedCost Available-for-sale Securities, Amortized Cost Basis USD 11.61M 2017-12-31 2018 Q2 10-Q 2018-08-09 0001564590-18-021125
us-gaap AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss USD 19,000 2017-12-31 2018 Q2 10-Q 2018-08-09 0001564590-18-021125
us-gaap AvailableForSaleSecuritiesCurrent Available-for-sale Securities, Current USD 204.87M 2021-09-30 2021 Q3 10-Q 2021-11-03 0001564590-21-054030
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 282.20M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 282.20M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Greater than or Equal to One Year Security 117 2018-06-30 2018 Q2 10-Q 2018-08-09 0001564590-18-021125
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 677.61M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap CashAndCashEquivalentsFairValueDisclosure Cash and Cash Equivalents, Fair Value Disclosure USD 553.33M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD -5.66M 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-01 0001564590-19-028043
us-gaap CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect USD 8.74M 2015-01-01 2015-06-30 2015 Q2 10-Q 2015-08-14 0001193125-15-291529
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 11.25M 2016-03-31 2016 Q1 10-Q 2016-05-10 0001564590-16-018987
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 36.63M 2022-12-31 2022 FY 10-K 2023-02-10 0001564590-23-001685
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 677.81M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect USD 512.01M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 32.90M 2023-01-01 2023-06-30 2023 Q2 10-Q 2023-07-26 0000950170-23-034773
us-gaap CashFDICInsuredAmount Cash, FDIC Insured Amount USD 250,000 2015-03-31 2015 Q1 10-Q 2015-06-12 0001193125-15-220837
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 1.5 2016-04-13 2023 FY 10-K 2024-02-07 0000950170-24-012322
us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights shares 7.50M 2016-04-13 2023 FY 10-K 2024-02-07 0000950170-24-012322
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 7.50M 2016-04-13 2017 Q3 10-Q 2017-11-08 0001564590-17-022829
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 23.58M 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 300.00M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 127.52M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 127.52M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap CommonStockValue Common Stock, Value, Issued USD 1,000 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -471.61M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ConvertibleLongTermNotesPayable Convertible Notes Payable, Noncurrent USD 250.66M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ConvertibleNotesPayableCurrent Convertible Notes Payable, Current USD 3.45M 2017-12-31 2018 FY 10-K 2019-03-13 0001564590-19-007584
us-gaap CurrentFederalStateAndLocalTaxExpenseBenefit Current Federal, State and Local, Tax Expense (Benefit) USD 1,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 1,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DebtConversionConvertedInstrumentAmount1 Debt Conversion, Converted Instrument, Amount USD 456,412 2015-01-01 2015-12-31 2016 FY 10-K 2017-03-21 0001564590-17-004911
us-gaap DebtConversionConvertedInstrumentSharesIssued1 Debt Conversion, Converted Instrument, Shares Issued shares 57,046 2015-05-03 2015-05-04 2015 FY 10-K 2016-03-08 0001564590-16-014212
us-gaap DebtInstrumentInterestRateDuringPeriod Debt Instrument, Interest Rate During Period pure 0.05 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-13 0001564590-19-007584
us-gaap DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage pure 0.05 2016-12-31 2017 Q1 10-Q 2017-05-10 0001564590-17-010332
us-gaap DebtSecuritiesAvailableForSaleGainLoss Debt Securities, Available-for-sale, Gain (Loss) USD 0 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-04-30 0001193125-26-193315
us-gaap DebtSecuritiesAvailableForSaleRealizedGainLoss Debt Securities, Available-for-sale, Realized Gain (Loss) USD 30,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Security 113 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance shares 1.00M 2014-02-28 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap DeferredCompensationArrangementWithIndividualExercisePrice Deferred Compensation Arrangement with Individual, Exercise Price USD/shares 0.01 2014-02-01 2014-02-28 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD -60.36M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredFederalStateAndLocalTaxExpenseBenefit Deferred Federal, State and Local, Tax Expense (Benefit) USD -100.67M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredFinanceCostsNoncurrentNet Debt Issuance Costs, Noncurrent, Net USD 158,842 2016-06-30 2016 Q2 10-Q 2016-08-11 0001564590-16-024067
us-gaap DeferredForeignIncomeTaxExpenseBenefit Deferred Foreign Income Tax Expense (Benefit) USD -19.56M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 12,000 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006766
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD -20.76M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 134.13M 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 264.98M 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 247,000 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 68.18M 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsDomestic Deferred Tax Assets, Operating Loss Carryforwards, Domestic USD 194.70M 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsForeign Deferred Tax Assets, Operating Loss Carryforwards, Foreign USD 156.10M 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal Deferred Tax Assets, Operating Loss Carryforwards, State and Local USD 110.60M 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration USD 17.70M 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 0 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 58.26M 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 4.24M 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities USD 174,000 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 264.74M 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 247,000 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DeferredTaxLiabilitiesOther Deferred Tax Liabilities, Other USD 223,000 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap DepositsAssetsNoncurrent Deposits Assets, Noncurrent USD 113,000 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -4.03 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.21 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-04-27 0001564590-22-016129
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -4.03 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.17 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006766
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure 0 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure 0 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-21 0001564590-17-004911
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.01 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.06 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap EffectiveIncomeTaxRateReconciliationTaxExemptIncome Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD -10,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 62,000 2015-05-31 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Share-based Payment Arrangement, Expense, Tax Benefit USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap FinanceLeaseLiability Finance Lease, Liability USD 0 2019-01-01 2019 FY 10-K 2020-02-26 0001564590-20-006766
us-gaap FinancialLiabilitiesFairValueDisclosure Financial Liabilities Fair Value Disclosure USD 1.40M 2017-12-31 2018 FY 10-K 2019-03-13 0001564590-19-007584
us-gaap ForeignCurrencyTransactionGainBeforeTax Foreign Currency Transaction Gain, before Tax USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-07 0000950170-24-012322
us-gaap ForeignCurrencyTransactionGainLossBeforeTax Foreign Currency Transaction Gain (Loss), before Tax USD -9,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ForeignCurrencyTransactionLossBeforeTax Foreign Currency Transaction Loss, before Tax USD 258,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-10 0001564590-23-001685
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 51.13M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -203.52M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -359.64M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD -156.12M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 1,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 100.67M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap IncomeTaxReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006766
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -75.52M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 4.22M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 236,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 1,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 22.64M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap IncomeTaxReconciliationTaxExemptIncome Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount USD -565,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 28.88M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap IncreaseDecreaseInAccountsPayableRelatedParties Increase (Decrease) in Accounts Payable, Related Parties USD -712 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-08 0001564590-16-014212
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD 27.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap IncreaseDecreaseInDepositOtherAssets Increase (Decrease) in Deposit Assets USD -40,659 2016-01-01 2016-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004757
us-gaap IncreaseDecreaseInDeposits Increase (Decrease) in Deposits USD -79,225 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-08 0001564590-16-014212
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -469,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap IncreaseDecreaseInOtherAccruedLiabilities Increase (Decrease) in Other Accrued Liabilities USD 3.31M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-10-26 0001564590-22-035295
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 3.39M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap IncrementalCommonSharesAttributableToConversionOfDebtSecurities Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities shares 656,716 2018-01-01 2018-03-31 2019 Q1 10-Q 2019-05-02 0001564590-19-015390
us-gaap InterestExpense Interest Expense USD 24,000 2018-01-01 2018-03-31 2019 Q1 10-Q 2019-05-02 0001564590-19-015390
us-gaap InterestExpenseNonoperating InterestExpenseNonoperating USD 88,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD 10.35M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-07-29 0001193125-26-324219
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 122,739 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004757
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 81,000 2018-01-01 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006766
us-gaap InterestPayableCurrent Interest Payable, Current USD 22,000 2017-12-31 2018 FY 10-K 2019-03-13 0001564590-19-007584
us-gaap InvestmentIncomeAmortizationOfPremium Investment Income, Amortization of Premium USD 1.22M 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-10 0001564590-23-001685
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 14.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap InvestmentIncomeNetAmortizationOfDiscountAndPremium Investment Income, Net, Amortization of Discount and Premium USD 5.50M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-10-25 0000950170-23-055259
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 116,000 2021-09-30 2021 Q3 10-Q 2021-11-03 0001564590-21-054030
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 29,000 2021-09-30 2021 Q3 10-Q 2021-11-03 0001564590-21-054030
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 29,000 2019-09-30 2019 Q3 10-Q 2019-11-05 0001564590-19-040424
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 29,000 2020-06-30 2020 Q2 10-Q 2020-07-29 0001564590-20-034329
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 29,000 2020-12-31 2020 FY 10-K 2021-02-17 0001564590-21-006406
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 87,000 2021-09-30 2021 Q3 10-Q 2021-11-03 0001564590-21-054030
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 1,000 2021-09-30 2021 Q3 10-Q 2021-11-03 0001564590-21-054030
us-gaap Liabilities Liabilities USD 388.57M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 977.17M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap LiabilitiesCurrent Liabilities, Current USD 133.90M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap LiabilitiesNoncurrent Liabilities, Noncurrent USD 254.67M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap LiabilityForUncertainTaxPositionsNoncurrent Liability for Uncertainty in Income Taxes, Noncurrent USD 0 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 633.21M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 62.30M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012501
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 256.14M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD -29.63M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012501
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -377.34M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD -5.30M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012501
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -469.53M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -4.92M 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-05-02 0001564590-19-015390
us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Net Income (Loss) Available to Common Stockholders, Diluted USD -4.92M 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-05-02 0001564590-19-015390
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-10-23 0000950170-24-116708
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap OperatingExpenses Operating Expenses USD 483.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -483.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap OperatingLeaseCost Operating Lease, Cost USD 169,000 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-07-27 0001564590-22-026717
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 683,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 4.04M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 24,000 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 4.01M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 3.85M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 400,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 116,000 2021-09-30 2021 Q3 10-Q 2021-11-03 0001564590-21-054030
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 343,000 2020-12-31 2020 FY 10-K 2021-02-17 0001564590-21-006406
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 29,000 2018-09-30 2018 Q3 10-Q 2018-11-07 0001564590-18-028101
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 29,000 2019-09-30 2019 Q3 10-Q 2019-11-05 0001564590-19-040424
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 29,000 2020-09-30 2020 Q3 10-Q 2020-10-28 0001564590-20-048398
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 29,000 2021-09-30 2021 Q3 10-Q 2021-11-03 0001564590-21-054030
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 87,000 2021-09-30 2021 Q3 10-Q 2021-11-03 0001564590-21-054030
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 243,000 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-03 0001564590-21-054030
us-gaap OperatingLeasesRentExpenseSubleaseRentals1 Operating Leases, Rent Expense, Sublease Rentals USD 19,737 2015-07-06 2015-07-07 2015 FY 10-K 2016-03-08 0001564590-16-014212
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.09 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 51.74M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 80,000 2015-09-30 2015 Q3 10-Q 2015-11-05 0001564590-15-009694
us-gaap OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax USD -9,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -2.07M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 14.30M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock USD 6.79M 2022-01-01 2022-12-31 2024 FY 10-K 2025-02-26 0000950170-25-027824
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 37,000 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-04-26 0000950170-23-014883
us-gaap PaymentsRelatedToTaxWithholdingForShareBasedCompensation Payment, Tax Withholding, Share-based Payment Arrangement USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap PaymentsToAcquireInvestments Payments to Acquire Investments USD 154.77M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 3.18M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ProceedsFromConvertibleDebt Proceeds from Convertible Debt USD 251.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 297.27M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised USD 2.22M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ProceedsFromNotesPayable Proceeds from Notes Payable USD 2.50M 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-08 0001564590-16-014212
us-gaap ProceedsFromRepurchaseOfEquity Proceeds from (Repurchase of) Equity USD -38 2015-01-01 2015-09-30 2015 Q3 10-Q 2015-11-05 0001564590-15-009694
us-gaap ProceedsFromSaleMaturityAndCollectionsOfInvestments Proceeds from Sale, Maturity and Collection of Investments USD 372.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ProceedsFromSaleOfAvailableForSaleSecurities Proceeds from Sale of Available-for-sale Securities USD 0 2018-01-01 2018-06-30 2018 Q2 10-Q 2018-08-09 0001564590-18-021125
us-gaap ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Proceeds from Sale of Debt Securities, Available-for-sale USD 38.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ProceedsFromSaleOfShortTermInvestments Proceeds from Sale of Short-term Investments USD 38.47M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 300,000 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-04-24 0000950170-25-058129
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 19,609 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-08 0001564590-17-022829
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -469.53M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap RealizedInvestmentGainsLosses Realized Investment Gains (Losses) USD 30,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap RepaymentsOfConvertibleDebt Repayments of Convertible Debt USD 3.83M 2018-01-01 2018-12-31 2019 FY 10-K 2020-02-26 0001564590-20-006766
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 432.71M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 202,000 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.32B 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap Revenues Revenues USD 0 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012501
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 4.18M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 39.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.855 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.04 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised shares 3.62M 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-07 0000950170-24-012322
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number shares 951,188 2021-03-31 2021 Q1 10-Q 2021-04-28 0001564590-21-021430
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 81.00M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 3.82M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 12.3 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 389.00M 2021-01-01 2021-12-31 2022 FY 10-K 2023-02-10 0001564590-23-001685
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 1.42M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 24.68 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 96.00M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 6.11M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 18.24 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 347,894 2015-06-30 2015 Q2 10-Q 2015-08-14 0001193125-15-291529
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 8.87 2015-06-30 2015 Q2 10-Q 2015-08-14 0001193125-15-291529
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value USD 11.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period shares 0 2015-01-01 2015-03-31 2015 Q1 10-Q 2015-06-12 0001193125-15-220837
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 12.68 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 33.52 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap SharePrice Share Price USD/shares 0.01 2016-04-13 2023 FY 10-K 2024-02-07 0000950170-24-012322
us-gaap SharesIssuedPricePerShare Shares Issued, Price Per Share USD/shares 1.25 2016-04-13 2023 FY 10-K 2024-02-07 0000950170-24-012322
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 588.60M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD 588.60M 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap StockIssued1 Stock Issued USD 1.80M 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-13 0001564590-19-007584
us-gaap StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Stock Issued During Period, Shares, Employee Stock Purchase Plans shares 0 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-04-24 0000950170-25-058129
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 0 2019-01-01 2019-12-31 2023 FY 10-K 2024-02-07 0000950170-24-012322
us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardGross Stock Issued During Period, Shares, Restricted Stock Award, Gross shares 84,000 2015-01-01 2015-09-30 2015 Q3 10-Q 2015-11-05 0001564590-15-009694
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 146,106 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 1.20M 2016-01-01 2016-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004757
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 73,141 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004757
us-gaap StockIssuedDuringPeriodValueIssuedForServices Stock Issued During Period, Value, Issued for Services USD 28,760 2015-01-01 2015-12-31 2016 FY 10-K 2017-03-21 0001564590-17-004911
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 379.57M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap StockIssuedDuringPeriodValueShareBasedCompensationGross Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture USD 2.22M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap StockRepurchasedDuringPeriodValue Stock Repurchased During Period, Value USD 38 2015-01-01 2015-12-31 2016 FY 10-K 2017-03-21 0001564590-17-004911
us-gaap StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased Stock Repurchase Program, Number of Shares Authorized to be Repurchased shares 633,810 2015-05-31 2024 Q1 10-Q 2024-04-25 0000950170-24-047833
us-gaap StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased shares 366,190 2015-05-31 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap TreasuryStockCommonShares Treasury Stock, Common, Shares shares 0 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap TreasuryStockShares Treasury Stock, Shares shares 2.19M 2023-03-31 2023 Q1 10-Q 2023-04-26 0000950170-23-014883
us-gaap TreasuryStockValue Treasury Stock, Value USD 0 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap TreasuryStockValueAcquiredCostMethod Treasury Stock, Value, Acquired, Cost Method USD 6.79M 2022-01-01 2022-12-31 2024 FY 10-K 2025-02-26 0000950170-25-027824
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 0 2025-12-31 2025 FY 10-K 2026-02-11 0001193125-26-046876
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 116.64M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 77.41M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-04-27 0001564590-22-016129
us-gaap WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation shares 30,211 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap WeightedAverageNumberOfSharesIssuedBasic Weighted Average Number of Shares Issued, Basic shares 116.67M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 116.64M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-10-29 0001193125-26-436432

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →